705 related articles for article (PubMed ID: 25796551)
1. Gonadotrophin-releasing hormone agonists for fertility preservation: unraveling the enigma?
Hasky N; Uri-Belapolsky S; Goldberg K; Miller I; Grossman H; Stemmer SM; Ben-Aharon I; Shalgi R
Hum Reprod; 2015 May; 30(5):1089-101. PubMed ID: 25796551
[TBL] [Abstract][Full Text] [Related]
2. GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro.
Bildik G; Akin N; Senbabaoglu F; Sahin GN; Karahuseyinoglu S; Ince U; Taskiran C; Selek U; Yakin K; Guzel Y; Ayhan C; Alper E; Cetiner M; Balaban B; Mandel NM; Esen T; Iwase A; Urman B; Oktem O
Hum Reprod; 2015 Dec; 30(12):2912-25. PubMed ID: 26466909
[TBL] [Abstract][Full Text] [Related]
3. Ceramide-1-phosphate has protective properties against cyclophosphamide-induced ovarian damage in a mice model of premature ovarian failure.
Pascuali N; Scotti L; Di Pietro M; Oubiña G; Bas D; May M; Gómez Muñoz A; Cuasnicú PS; Cohen DJ; Tesone M; Abramovich D; Parborell F
Hum Reprod; 2018 May; 33(5):844-859. PubMed ID: 29534229
[TBL] [Abstract][Full Text] [Related]
4. Both in vivo FSH depletion and follicular exposure to Gonadotrophin-releasing hormone analogues in vitro are not effective to prevent follicular depletion during chemotherapy in mice.
Horicks F; Van Den Steen G; Gervy C; Clarke HJ; Demeestere I
Mol Hum Reprod; 2018 Apr; 24(4):221-232. PubMed ID: 29438534
[TBL] [Abstract][Full Text] [Related]
5. Dual suppression of follicle activation pathways completely prevents the cyclophosphamide-induced loss of ovarian reserve.
Kashi O; Roness H; Spector I; Derech-Haim S; Meirow D
Hum Reprod; 2023 Jun; 38(6):1086-1098. PubMed ID: 37015102
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal study of AMH variations in 122 Adolescents and Young Adults (AYA) and non-AYA lymphoma patients to evaluate the chemo-induced ovarian toxicity to further personalise fertility preservation counselling.
Decanter C; Delepine J; Behal H; Manier S; Bruno B; Barbatti M; Robin C; Labreuche J; Morschhauser F; Pigny P
Hum Reprod; 2021 Sep; 36(10):2743-2752. PubMed ID: 34417822
[TBL] [Abstract][Full Text] [Related]
7. Cryopreservation of in vitro matured oocytes in addition to ovarian tissue freezing for fertility preservation in paediatric female cancer patients before and after cancer therapy.
Abir R; Ben-Aharon I; Garor R; Yaniv I; Ash S; Stemmer SM; Ben-Haroush A; Freud E; Kravarusic D; Sapir O; Fisch B
Hum Reprod; 2016 Apr; 31(4):750-62. PubMed ID: 26848188
[TBL] [Abstract][Full Text] [Related]
8. The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation.
Winship AL; Griffiths M; Lliberos Requesens C; Sarma U; Phillips KA; Hutt KJ
Hum Reprod; 2020 Aug; 35(8):1864-1874. PubMed ID: 32604417
[TBL] [Abstract][Full Text] [Related]
9. Transplantation of adipose-derived stem cells combined with collagen scaffolds restores ovarian function in a rat model of premature ovarian insufficiency.
Su J; Ding L; Cheng J; Yang J; Li X; Yan G; Sun H; Dai J; Hu Y
Hum Reprod; 2016 May; 31(5):1075-86. PubMed ID: 26965432
[TBL] [Abstract][Full Text] [Related]
10. Anti-Mullerian hormone attenuates both cyclophosphamide-induced damage and PI3K signalling activation, while rapamycin attenuates only PI3K signalling activation, in human ovarian cortex in vitro.
Rosario R; Stewart HL; Spears N; Telfer EE; Anderson RA
Hum Reprod; 2024 Feb; 39(2):382-392. PubMed ID: 38070496
[TBL] [Abstract][Full Text] [Related]
11. Ovarian response prediction in GnRH antagonist treatment for IVF using anti-Müllerian hormone.
Hamdine O; Eijkemans MJ; Lentjes EW; Torrance HL; Macklon NS; Fauser BC; Broekmans FJ
Hum Reprod; 2015 Jan; 30(1):170-8. PubMed ID: 25355590
[TBL] [Abstract][Full Text] [Related]
12. Development and characterization of a novel long-acting recombinant follicle stimulating hormone agonist by fusing Fc to an FSH-β subunit.
Zhang YL; Guo KP; Ji SY; Liu XM; Wang P; Wu J; Gao L; Jiang TQ; Xu T; Fan HY
Hum Reprod; 2016 Jan; 31(1):169-82. PubMed ID: 26621853
[TBL] [Abstract][Full Text] [Related]
13. The cyto-protective effects of LH on ovarian reserve and female fertility during exposure to gonadotoxic alkylating agents in an adult mouse model.
Del Castillo LM; Buigues A; Rossi V; Soriano MJ; Martinez J; De Felici M; Lamsira HK; Di Rella F; Klinger FG; Pellicer A; Herraiz S
Hum Reprod; 2021 Aug; 36(9):2514-2528. PubMed ID: 34333622
[TBL] [Abstract][Full Text] [Related]
14. Ovarian reserve after treatment with alkylating agents during childhood.
Thomas-Teinturier C; Allodji RS; Svetlova E; Frey MA; Oberlin O; Millischer AE; Epelboin S; Decanter C; Pacquement H; Tabone MD; Sudour-Bonnange H; Baruchel A; Lahlou N; De Vathaire F
Hum Reprod; 2015 Jun; 30(6):1437-46. PubMed ID: 25801499
[TBL] [Abstract][Full Text] [Related]
15. [Protective effect of GnRH analogues on the reproductive capacity of women with neoplasia or autoimmune disease who require chemotherapy. Final results of a phase ii clinical trial].
Gris-Martínez JM; Trillo-Urrutia L; Gómez-Cabeza JJ; Encabo-Duró G
Med Clin (Barc); 2016 Feb; 146(3):97-103. PubMed ID: 26194532
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic ovarian preservation in young women undergoing chemotherapy.
Chahvar ST; Al-Shawaf T; Tranquilli AL
Curr Med Chem; 2014; 21(2):223-9. PubMed ID: 24164203
[TBL] [Abstract][Full Text] [Related]
17. Loss of LH-induced down-regulation of anti-Müllerian hormone receptor expression may contribute to anovulation in women with polycystic ovary syndrome.
Pierre A; Peigné M; Grynberg M; Arouche N; Taieb J; Hesters L; Gonzalès J; Picard JY; Dewailly D; Fanchin R; Catteau-Jonard S; di Clemente N
Hum Reprod; 2013 Mar; 28(3):762-9. PubMed ID: 23321213
[TBL] [Abstract][Full Text] [Related]
18. Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy.
Lee DY; Park YH; Lee JE; Choi D
Breast Cancer Res Treat; 2018 Oct; 171(3):649-656. PubMed ID: 29943121
[TBL] [Abstract][Full Text] [Related]
19. GnRH Agonist Triggering Modulates PEDF to VEGF Ratio Inversely to hCG in Granulosa Cells.
Miller I; Chuderland D; Ron-El R; Shalgi R; Ben-Ami I
J Clin Endocrinol Metab; 2015 Nov; 100(11):E1428-36. PubMed ID: 26308290
[TBL] [Abstract][Full Text] [Related]
20. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome.
Scotti L; Irusta G; Abramovich D; Tesone M; Parborell F
Mol Cell Endocrinol; 2011 Mar; 335(2):116-25. PubMed ID: 21238536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
